Abstract
Immunofluorescence on HEp2-cells is the standard diagnostic assay for the detection of anti-nuclear antibodies (ANA). Cytoplasmic speckled patterns are a common finding, and are associated with various antibodies, including anti-synthetase antibodies. However, classic ENA testing generally identifies only anti-Jo-1. Moreover, anti-synthetase syndrome is increasingly recognized as a pleomorphic entity, possibly presenting as isolated arthritis or interstitial lung disease. Sera referred for routine ANA testing were selected on the basis of the presence of a fine dense speckled cytoplasmic pattern (254 samples) and compared to control sera with negative cytoplasm (239 samples). All 493 samples were tested with a commercial synthetase profile dot-blot (D TEK - Alphadia-Alifax) including anti-Jo1, anti-PL7, anti-PL12, anti-EJ, anti-OJ, anti-KS, anti-ZO, anti-HA, anti-SRP, and anti-Ribosome P0. Retrospective clinical data was searched for positive patients. Dot-blot identified 18/254 (7.1%) positive sera in the samples with a cytoplasmic fluorescence pattern and 4/239 (1.7%) in the control group (χ2 = 8.4627; p = 0.003625). Blot intensity was more intense in samples with concordant cytoplasmic staining (cytoplasmic negative 27 ± 12.4; cytoplasmic positive 53.9 27 ± 27.7; p = 0.0027). In the positive samples, 8/18 had a highly compatible diagnosis (myositis, interstitial lung disease, arthritis), 7/18 an uncharacterized connective tissue disease, and 3 a diagnosis not associated with the presence of anti-synthetase antibodies. We evaluated the performance of a dot-blot assay for anti-cytoplasmic antibodies in a serologic cohort presenting a cytoplasmic speckled pattern found during routine ANA testing. This algorithm enabled the identification of a significant quota of patients with rare anti-synthetase antibodies and an incomplete or atypical clinical picture. Reflex testing strategies of speckled cytoplasmic patterns with multiplex assays containing cytoplasm-specific antigens, as opposed to standard ENA testing, may yield important data and for this reason should be implemented in routine ANA testing.
Similar content being viewed by others
References
Meroni PL, Schur PH. ANA screening: an old test with new recommendations. Ann Rheum Dis. 2010;69(8):1420–2. https://doi.org/10.1136/ard.2009.127100.
Stinton LM, Eystathioy T, Selak S, Chan EKL, Fritzler MJ. Autoantibodies to protein transport and messenger RNA processing pathways: endosomes, lysosomes, Golgi complex, proteasomes, assemblyosomes, exosomes, and GW bodies. Clin Immunol. 2004;110(1):30–44. https://doi.org/10.1016/j.clim.2003.10.005.
Koh WH, Dunphy J, Whyte J, Dixey J, McHugh NJ. Characterisation of anticytoplasmic antibodies and their clinical associations. Ann Rheum Dis. 1995;54(4):269–73. https://doi.org/10.1136/ard.54.4.269.
Craig WY, Ledue TB, Collins MF, Meggison WE, Leavitt LF, Ritchie RF. Serologic associations of anti-cytoplasmic antibodies identified during anti-nuclear antibody testing. Clin Chem Lab Med. 2006;44(10):1283–6. https://doi.org/10.1515/CCLM.2006.232.
Satoh M, Chan EKL, Ho LA, Rose KM, Parks CG, Cohn RD, et al. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum. 2012;64(7):2319–27. https://doi.org/10.1002/art.34380.
Hoffman IEA, Peene I, Veys EM, De Keyser F. Detection of specific antinuclear reactivities in patients with negative anti-nuclear antibody immunofluorescence screening tests. Clin Chem. 2002;48(12):2171–6.
Agmon-Levin N, Damoiseaux J, Kallenberg C, Sack U, Witte T, Herold M , Bossuyt X., Musset L., Cervera R., Plaza-Lopez A., Dias C., Sousa M.J., Radice A., Eriksson C., Hultgren O., Viander M., Khamashta M., Regenass S., Andrade L.E.C., Wiik A., Tincani A., Rönnelid J., Bloch D.B., Fritzler M.J., Chan E.K.L., Garcia-de la Torre I., Konstantinov K.N., Lahita R., Wilson M., Vainio O., Fabien N., Sinico R.A., Meroni P., Shoenfeld Y.et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis 2014;73:17–23. doi:https://doi.org/10.1136/annrheumdis-2013-203863, 1.
Chan EKL, Damoiseaux J, Carballo OG, Conrad K, de Melo Cruvinel W, Francescantonio PLC, Fritzler MJ, Garcia-de la Torre I, Herold M, Mimori T, Satoh M, von Mühlen CA, Andrade LECet al. Report of the first international consensus on standardized nomenclature of antinuclear antibody HEp-2 cell patterns 2014–2015. Front Immunol 2015;6. doi:https://doi.org/10.3389/fimmu.2015.00412.
Váncsa A, Gergely L, Ponyi A, Lakos G, Németh J, Szodoray P, et al. Myositis-specific and myositis-associated antibodies in overlap myositis in comparison to primary dermatopolymyositis: relevance for clinical classification: retrospective study of 169 patients. Joint Bone Spine. 2010;77(2):125–30. https://doi.org/10.1016/j.jbspin.2009.08.008.
Ghirardello A, Bendo R, Rampudda ME, Bassi N, Zampieri S, Doria A. Commercial blot assays in the diagnosis of systemic rheumatic diseases. Autoimmun Rev. 2009;8(8):645–9. https://doi.org/10.1016/j.autrev.2009.02.012.
Ghirardello A, Rampudda M, Ekholm L, Bassi N, Tarricone E, Zampieri S, et al. Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay. Rheumatology (Oxford). 2010;49(12):2370–4. https://doi.org/10.1093/rheumatology/keq281.
Rönnelid J, Barbasso Helmers S, Storfors H, Grip K, Rönnblom L, Franck-Larsson K, et al. Use of a commercial line blot assay as a screening test for autoantibodies in inflammatory myopathies. Autoimmun Rev. 2009;9(1):58–61. https://doi.org/10.1016/j.autrev.2009.03.005.
Wiik AS, Høier-Madsen M, Forslid J, Charles P, Meyrowitsch J. Antinuclear antibodies: a contemporary nomenclature using HEp-2 cells. J Autoimmun. 2010;35(3):276–90. https://doi.org/10.1016/j.jaut.2010.06.019.
Damoiseaux J, von Mühlen CA, Garcia-De La Torre I, Carballo OG, de Melo CW, Francescantonio PLC, et al. International consensus on ANA patterns (ICAP): the bumpy road towards a consensus on reporting ANA results. Autoimmun Highlights. 2016;7(1):1–8. https://doi.org/10.1007/s13317-016-0075-0.
Mahler M, Miller FW, Fritzler MJ. Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. Autoimmun Rev. 2014;13(4-5):367–71. https://doi.org/10.1016/j.autrev.2014.01.022.
Picard C, Vincent T, Lega JC, Hue S, Fortenfant F, Lakomy D, et al. Heterogeneous clinical spectrum of anti-SRP myositis and importance of the methods of detection of anti-SRP autoantibodies: a multicentric study. Immunol Res. 2016;64(3):677–86. https://doi.org/10.1007/s12026-015-8774-6.
Pasoto SG, Viana VST, Bonfa E. The clinical utility of anti-ribosomal P autoantibodies in systemic lupus erythematosus. Expert Rev Clin Immunol. 2014;10(11):1493–503. https://doi.org/10.1586/1744666X.2014.966692.
Imura Y, Shirai Y, Nojima T, Nakashima R, Yamagata H, Miyachi K, et al. NEFA/nucleobindin-2 is a target autoantigen of the anti-Wa antibody and is associated with transfer RNA. Mod Rheumatol. 2012;22(5):685–94. https://doi.org/10.1007/s10165-011-0582-9.
Gelpi C, Sontheimer EJ, Rodriguez-Sanchez JL. Autoantibodies against a serine tRNA-protein complex implicated in cotranslational selenocysteine insertion. Proc Natl Acad Sci U S A. 1992;89(20):9739–43. https://doi.org/10.1073/pnas.89.20.9739.
Selva-O’Callaghan A, Trallero-Araguás E, Martínez MA, Labrador-Horrillo M, Pinal-Fernández I, Grau-Junyent JM, et al. Inflammatory myopathy: diagnosis and clinical course, specific clinical scenarios and new complementary tools. Expert Rev Clin Immunol. 2015;11(6):737–47. https://doi.org/10.1586/1744666X.2015.1035258.
Targoff IN, Arnett FC, Berman L, O’Brien C, Reichlin M. Anti-KJ: a new antibody associated with the syndrome of polymyositis and interstitial lung disease. J Clin Invest. 1989;84(1):162–72. https://doi.org/10.1172/JCI114136.
Griffith KJ, Ryan JP, Senécal J-L, Fritzler MJ. The cytoplasmic linker protein CLIP-170 is a human autoantigen. Clin Exp Immunol. 2002;127(3):533–8. https://doi.org/10.1046/j.1365-2249.2002.01756.x.
Selak S, Chan EK, Schoenroth L, Senécal JL, Fritzler MJ. Early endosome antigen. 1: an autoantigen associated with neurological diseases. J Investig Med. 1999;47(6):311–8.
Matsushita M, Matsudaira R, Ikeda K, Nawata M, Tamura N, Takasaki Y. Anti-proteasome activator 28alpha is a novel anti-cytoplasmic antibody in patients with systemic lupus erythematosus and Sjögren’s syndrome. Mod Rheumatol. 2009;19(6):622–8. https://doi.org/10.1007/s10165-009-0215-8.
Scirè CA, Gonzalez-Gay MA, Selva-O’Callaghan A, Cavagna L, Selva-O’Callaghan A, Cavagna L. Clinical spectrum time course of interstitial pneumonia with autoimmune features in patients positive for antisynthetase antibodies. Respir Med. 2017; https://doi.org/10.1016/j.rmed.2017.03.028.
Cavagna L, Nuño L, Scirè CA, Govoni M, Longo FJL, Franceschini F, et al. Serum Jo-1 autoantibody and isolated arthritis in the antisynthetase syndrome: review of the literature and report of the experience of AENEAS collaborative group. Clin Rev Allergy Immunol. 2017;52(1):71–80. https://doi.org/10.1007/s12016-016-8528-9.
Acknowledgments
The authors thank Alphadia for kindly providing the reagents for autoantibody detection free of costs, and Dr. Chiara Derioni and Dr. Riccardo Favilli of Alifax for the technical assistance.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Infantino, M., Palterer, B., Biagiotti, R. et al. Reflex testing of speckled cytoplasmic patterns observed in routine ANA HEp-2 indirect immunofluorescence with a multiplex anti-synthetase dot-blot assay: a multicentric pilot study. Immunol Res 66, 74–78 (2018). https://doi.org/10.1007/s12026-017-8974-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12026-017-8974-3